Specialized Biotech ETF Rallies on MacroGenics Positive Trial Results
February 06, 2019 at 14:32 PM EST
A biotechnology sector-specific exchange traded fund specialized in tracking immunotherapy drugmakers bucked the broader market trends and surged Wednesday after MacroGenics (NasdaqGS: MGNX) announced upbeat breast cancer trail results. The Loncar Cancer Immunotheraphy ETF (NasdaqGM: CNCR), which...
